J.P. Morgan Maintains OW Rating On Nektar Therapeutics

J.P. Morgan reports that over the weekend, Nektar Therapeutics NKTR presented promising Ph2 data for NKTR-102 in second line metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium (SABCS) wherein the objective response rate improved since this summer's topline update (29% from 21%). As a result, J.P. Morgan is maintaining its OW rating on Nektar Therapeutics, which closed Friday at $14.06.